TRIMTECH Therapeutics’s incredible $31million seed funding haul will be deployed to develop treatments for severe ...

A Montreal-based retail expert says he believes this is the beginning of the end for the iconic 355-year-old Hudson's Bay brand as it goes through the creditor protection process.

Takes you closer to the games, movies and TV you love Issues delivered straight to your door or device If you ask me, Hideo ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

Meta is planning for QLC SSDs to reach capacities as large as 512TB and sees E1.S and E3 form factors as dead on arrival for ...

Haisco Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an androgen receptor (AR) ...

The author writes "The U.S. Copyright Office has long maintained that copyright protection extends only to works exhibiting ...

Since the confused rollout, Garmin has now issued confirmation that this is a stable update, version 13.35, with various bug ...

Last Sunday, the Israeli government announced the suspension of all humanitarian aid to Gaza after Hamas rejected the ceasefire extension proposed by U.S. Middle East envoy Steve Witkoff. Israeli ...

Karyopharm Therapeutics Inc.’s KPTI share price has surged by 10.77%, which has investors questioning if this is right time to sell.

Trimtech Therapeutics has closed a seed funding round of $31m (£25m) to advance its pipeline of CNS penetrant therapeutics.